ViGenCell바이젠셀

ViGenCell remains loss-making with minimal revenue, and its shares are down sharply over the past month.

ViGenCell is a Korean cell therapy developer whose trailing twelve months to H1 2026 show revenue of about ₩0.9B against an operating loss of about ₩14.1B. Cash of ₩15.6B and borrowings of ₩7.4B sit against negative free cash flow of about ₩11.6B, and the shares closed at ₩4,975 on 23 October 2026, roughly 13% lower over one month. The data gives no earnings-based valuation because profits are negative, and the company pays no dividend.

What stands out

• Revenue has collapsed: about ₩279M in 2024 and ₩23M in 2025, after none in 2021 to 2023, so the business is not yet generating meaningful sales.
• Operating losses have stayed in the ₩13B to ₩20B range every year since 2021, and the trailing operating margin is about -1,533%.
• Cash of ₩15.6B covers borrowings of ₩7.4B, but free cash flow of -₩11.6B over the trailing period suggests a limited runway at this burn rate, based only on these figures.
• The price-to-book ratio of 2.6 and price-to-sales of about 110.6 are high against a loss-making business, and the DCF fair value in the data (base ₩3,463) is below the current price.
• Foreign ownership eased slightly to 2.3% from 2.5% over 60 days, while the 20-day flows show foreign buying but institutional and retail net selling.

What to watch

• The half-year report for June 2026 was filed on 14 August; the next quarterly or annual figures will show whether losses and cash burn are narrowing.
• Pipeline progress for VT-EBV-N, VM-GD and VC-302 is not detailed in the data, so any clinical or regulatory updates are worth checking in company filings.
• The stock is about 71% below its 52-week high of ₩17,360, and the data shows no recent news headlines to explain the one-month decline.